Exchange: NYSE·Updated 04:04 PM EDT

BHC News

News
all
press releases
Bausch Health Pilot Study Shows Improved Cirrhosis Care Adherence
(RTTNews) - Bausch Health Companies Inc. (BHC, BHC.TO) and its gastroenterology unit Salix Pharmaceuticals, announced on Monday that a six-month pilot study of a standardized clinical pathway for Cirrhosis management improved adherence to guideline-based monitoring and treatment...
Nasdaq News: Markets
Bausch Health Pilot Study Shows Improved Cirrhosis Care Adherence
(RTTNews) - Bausch Health Companies Inc. (BHC, BHC.TO) and its gastroenterology unit Salix Pharmaceuticals, announced on Monday that a six-month pilot study of a standardized clinical pathway for Cirrhosis management improved adherence to guideline-based monitoring and treatment...
Nasdaq News: Markets
More News
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical PathwayPR NewswireLAVAL, QC, Oct. 12...
PR Newswire
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective...
Business Wire
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026PR NewswireLAVAL, QC, Oct. 6, 2026LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026...
PR Newswire
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
Zacks
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Zacks
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.
Zacks
Zacks Value Investor Highlights: FOXF, BHC and QNST
FOXF, BHC and QNST emerge as hidden-gem value stocks under $20, with low valuation metrics and notable earnings growth prospects.
Zacks
Screening for Hidden Gem Stocks Under $20
Are you tired of stocks over $100 or $1000? These three stocks are values but trade under $20.
Zacks
Best Value Stocks to Buy for September 22nd
BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.
Zacks

Advertisement|Remove ads.